Pilot Integrated Biomarker Study of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Resectable Metastatic Melanoma
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pepinemab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 04 Jun 2019 According to a Study design presented at the 55th ASCO meeting, as of 01 Feb 2019, 8 of 36 patients have been enrolled.
- 04 Jun 2019 Study design was presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 15 May 2019 According to a Vaccinex media release, estimated primary completion date of this study is second half of 2020, and this study being conducted at the UCLA School of Medicine